Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSmith & Nephew Regulatory News (SN.)

Share Price Information for Smith & Nephew (SN.)

Share Price is delayed by 15 minutes
Get Live Data
1,146.00    7.00 (0.61%)
Bid:
1,146.00
Ask:
1,146.50
Spread: 0.50 (0.044%)
Market Cap: £9.73b
SN. Live PriceLast checked at - London Stock Exchange

Intraday Smith & Nephew Share Chart

Directorate Change

8 Feb 2019 09:17

RNS Number : 4909P
Smith & Nephew Plc
08 February 2019
 

8 February 2019

DIRECTORATE CHANGES

Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, today  announces, in accordance with Listing Rule 9.6.11(2) R, that Ian Barlow will retire as Senior Independent Director and Non-Executive Director, and Michael Friedman will retire as Chair of the Ethics & Compliance Committee and Non-Executive Director at the conclusion of the Annual General Meeting (AGM) on 11 April 2019.

Roberto Quarta, Chair, said

"Ian Barlow and Michael Friedman have served Smith & Nephew for many years, 15 collectively. We will miss their great wisdom and experience. On behalf of the whole Board I would like to thank them for their dedicated service and wish them well for the future."

Following the AGM on 11 April 2019, and subject to their re-election as Directors of Smith & Nephew plc at the AGM, Robin Freestone will be appointed as Senior Independent Non-Executive Director, in place of Ian Barlow and Marc Owen will succeed Michael Friedman as Chair of the Ethics & Compliance Committee. Additionally, Robin Freestone and Erik Engstrom will become members of the Nomination & Governance Committee and Virginia Bottomley and Roland Diggelmann will become members of the Ethics & Compliance Committee.

 

Enquiries

 

Investors

Andrew SwiftSmith & Nephew

+44 (0) 20 7960 2285

 

Media

Charles ReynoldsSmith & Nephew

+44 (0) 1923 477314

Ben Atwell / Andrew WardFTI Consulting

+44 (0) 20 3727 1000

About Smith & Nephew

 

Smith & Nephew is a portfolio medical technology business with leadership positions in Orthopaedics, Advanced Wound Management and Sports Medicine. Smith & Nephew has more than 16,000 employees and a presence in more than 100 countries. Annual sales in 2018 were $4.9 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN). For more information about Smith & Nephew, please visit our corporate website www.smith-nephew.com and follow us on Twitter, LinkedIn or Facebook.

 

Forward-looking Statements

 

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.

 

◊ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAGCGDDUBGBGCI
Date   Source Headline
5th Jun 202612:12 pmRNSTransaction in Own Shares
4th Jun 20264:05 pmRNSDirector/PDMR Shareholding
3rd Jun 202611:21 amRNSDirector/PDMR Shareholding
3rd Jun 202610:35 amRNSAdmission to Trading
1st Jun 20263:10 pmRNSTotal Voting Rights
29th May 202610:37 amRNSTransaction in Own Shares
27th May 20269:31 amRNSPre Stabilisation Notice
22nd May 20261:32 pmRNSAdmission to Trading
22nd May 20269:58 amRNSTransaction in Own Shares
20th May 202611:25 amRNSDirector/PDMR Shareholding
19th May 20268:53 amRNSHolding(s) in Company
15th May 202612:28 pmRNSTransaction in Own Shares Replacement
15th May 202611:41 amRNSTransaction in Own Shares
14th May 20269:25 amRNSHolding(s) in Company
12th May 20264:03 pmRNSSterling Amount of Dividend
8th May 20267:00 amRNSShare Buyback Programme
6th May 20262:25 pmRNSResult of AGM
6th May 20267:00 amRNSSmith+Nephew First Quarter 2026 Trading Update
1st May 20261:10 pmRNSTotal Voting Rights
27th Apr 20267:00 amRNSExpert surgeons insights event for investors
22nd Apr 20268:46 amRNSNotice of Results
16th Apr 202611:12 amRNSDirector/PDMR Shareholding
15th Apr 20263:46 pmRNSDirector Declaration
14th Apr 20262:59 pmRNSReplacement: Annual Financial Report & AGM Notice
1st Apr 202612:23 pmRNSTotal Voting Rights
24th Mar 20264:16 pmRNSDirector/PDMR Shareholding
24th Mar 20268:45 amRNSHolding(s) in Company
16th Mar 20263:08 pmRNSAnnual Financial Report & Notice of AGM
16th Mar 20263:08 pmRNSAnnual Financial Report & Notice of AGM
10th Mar 20262:30 pmRNS-RSmith+Nephew launches next-generation ALLEVYN™ COMPLETE CARE Foam Dressing - designed for high performance in wound management and pressure injury prevention
5th Mar 20267:30 amRNSDirector Declaration
2nd Mar 20261:36 pmRNSTotal Voting Rights
2nd Mar 20267:00 amRNSFinal Results
5th Feb 202611:56 amRNSNotice of Results
2nd Feb 20264:00 pmRNSBLOCK LISTING SIX MONTHLY RETURN
2nd Feb 20263:05 pmRNSTotal Voting Rights
23rd Jan 20262:00 pmRNSDirector/PDMR Shareholding
21st Jan 20264:11 pmRNSCompletion of Acquisition
12th Jan 20264:30 pmRNSAcquisition of Integrity Orthopaedics
2nd Jan 202610:07 amRNSTotal Voting Rights
8th Dec 20257:00 amRNSNew Strategy and 2028 Financial Targets
1st Dec 20254:10 pmRNSTotal Voting Rights
19th Nov 202510:00 amRNSDirector/PDMR Shareholding
18th Nov 202510:18 amRNSHolding(s) in Company
12th Nov 20259:24 amRNSDirector/PDMR Shareholding
11th Nov 20254:40 pmRNSHolding(s) in Company
10th Nov 20251:46 pmRNSDirector/PDMR Shareholding
7th Nov 20259:38 amRNSDirector/PDMR Shareholding
7th Nov 20259:35 amRNSDirector/PDMR Shareholding
6th Nov 20257:01 amRNSDirectorate change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.